Becton, Dickinson and Company (NYSE:BDX) Updates FY 2025 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 14.300-14.600 for the period, compared to the consensus EPS estimate of 14.350. The company issued revenue guidance of $21.7 billion-$21.9 billion, compared to the consensus revenue estimate of $21.9 billion.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Piper Sandler increased their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $283.00.

Becton, Dickinson and Company Price Performance

BDX stock traded down $11.03 on Thursday, reaching $234.03. 1,754,869 shares of the company’s stock were exchanged, compared to its average volume of 2,029,463. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The firm has a market cap of $67.87 billion, a PE ratio of 39.43, a P/E/G ratio of 1.80 and a beta of 0.40. The stock has a fifty day moving average of $231.79 and a 200-day moving average of $234.09.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.78%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Becton, Dickinson and Company declared that its board has approved a stock buyback plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. This trade represents a 15.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. This trade represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 9,844 shares of company stock worth $2,210,716. 0.36% of the stock is currently owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.